Penn Spasm Frequency Scale (PSFS)
The Penn Spasm Frequency Scale is a validated self-report measure consisting of two parts: Part 1 assesses the frequency of muscle spasms (scored 0-4), and Part 2 assesses the severity of spasms (scored 1-3), used to quantify spasticity in adults with upper motor neuron syndrome.
Scale Structure and Scoring
The PSFS is a patient-reported outcome measure with two distinct components 1:
Part 1 - Spasm Frequency:
- 0 = No spasms
- 1 = Mild spasms induced by stimulation
- 2 = Infrequent full spasms occurring less than once per hour
- 3 = Spasms occurring more than once per hour
- 4 = Spasms occurring more than 10 times per hour
Part 2 - Spasm Severity:
- 1 = Mild
- 2 = Moderate
- 3 = Severe
Clinical Application in Upper Motor Neuron Syndrome
The PSFS serves as a complementary assessment tool to objective measures like the Modified Ashworth Scale when evaluating spasticity 2. While the Modified Ashworth Scale quantifies resistance to passive movement (scored 0-4, taking approximately 10 minutes to administer), the PSFS captures the patient's subjective experience of spontaneous spasm activity.
When to Use the PSFS
Use this scale when:
- Monitoring treatment response to antispasticity interventions (botulinum toxin injections, oral agents, intrathecal baclofen)
- Assessing functional impact of spasms on activities of daily living, hygiene, dressing, and positioning
- Tracking spasticity over time in chronic conditions (stroke, spinal cord injury, multiple sclerosis)
- Supplementing objective measures to capture the full spectrum of spasticity-related disability
Psychometric Properties
The PSFS demonstrates robust reliability in chronic spinal cord injury populations 1:
- Intra-rater reliability (5-10 days): 0.822 for Part 1 alone; 0.812 with Part 2 included
- Intra-rater reliability (4-6 weeks): 0.734 for Part 1 alone; 0.729 with Part 2 included
- Inter-rater reliability (within 3 days): 0.862 for Part 1 alone; 0.857 with Part 2 included
These weighted-kappa statistics fall in the "almost perfect" to "substantial" reliability categories, confirming the PSFS as a dependable outcome measure.
Integration with Treatment Algorithms
When spasticity is identified through clinical examination and PSFS scoring, treatment follows this hierarchy based on AHA/ASA guidelines 2:
For localized spasticity (high PSFS scores in specific muscle groups):
- First-line: Botulinum toxin injections into affected upper limb muscles (Class I, Level A evidence) or lower limb muscles interfering with gait (Class I, Level A evidence)
For generalized spasticity (high PSFS scores across multiple regions):
- Consider: Oral antispasticity agents, though dose-limiting sedation is common (Class IIa, Level A evidence)
For severe, refractory spasticity (persistently high PSFS despite other interventions):
- Consider: Intrathecal baclofen therapy as early as 3-6 months after stroke onset (Class IIb, Level A evidence)
Clinical Caveats
Important limitations:
- The PSFS relies on patient self-report and may not correlate perfectly with objective spasticity measures
- Adding Part 2 (severity) slightly decreases reliability compared to Part 1 alone, though both remain clinically useful 1
- The scale was primarily validated in spinal cord injury; extrapolation to other upper motor neuron conditions (stroke, cerebral palsy, multiple sclerosis) is reasonable but has less direct evidence
- PSFS scores should be interpreted alongside functional impact measures, as spasticity frequency doesn't always correlate with disability burden
Do not use PSFS as the sole determinant for invasive interventions like intrathecal baclofen pumps—combine with objective measures (Modified Ashworth Scale), functional assessments, and quality of life evaluations to guide treatment decisions 2.